1. Home
  2. SLN vs CNNE Comparison

SLN vs CNNE Comparison

Compare SLN & CNNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$11.51

Market Cap

678.0M

Sector

Health Care

ML Signal

HOLD

CNNE

Cannae Holdings Inc.

HOLD

Current Price

$15.79

Market Cap

686.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLN
CNNE
Founded
1994
2014
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
678.0M
686.6M
IPO Year
2010
2017

Fundamental Metrics

Financial Performance
Metric
SLN
CNNE
Price
$11.51
$15.79
Analyst Decision
Buy
Buy
Analyst Count
5
4
Target Price
$42.60
$20.25
AVG Volume (30 Days)
647.9K
466.8K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
4.47%
EPS Growth
N/A
N/A
EPS
N/A
0.12
Revenue
$559,000.00
$499,700,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$130.33
Revenue Growth
N/A
3.37
52 Week Low
$4.19
$10.46
52 Week High
$17.58
$19.01

Technical Indicators

Market Signals
Indicator
SLN
CNNE
Relative Strength Index (RSI) 42.56 N/A
Support Level $4.70 N/A
Resistance Level $15.28 N/A
Average True Range (ATR) 0.58 0.00
MACD -0.23 0.00
Stochastic Oscillator 10.46 0.00

Price Performance

Historical Comparison
SLN
CNNE

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About CNNE Cannae Holdings Inc.

Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.

Share on Social Networks: